Перейти к содержимому


  • Публикации

  • Зарегистрирован

  • Посещение


0 Neutral

О amandahao

  • Звание

Previous Fields

  • Обращение
    на "Ты"
  1. Meet Ddu in Dubai–The First Medical Exhibition of 2018

    The Arab Health Exhibition 2018 will be held at the Dubai International Convention & Exhibition Centre from January 29th to February 1st, 2018. Ddu, the leading global pharmaceutical & medical device B2B online platform, will once again attend the exhibition, showcasing the changes that the Internet has brought to cross-border medical trade to the visitors in Dubai, as well as our global audience. As the largest international and professional exhibition in the Middle East, Arab Health is well-known to hospitals and medical device agents in Arab countries. According to statistics, this exhibition will attract more than 4,200 medical device products exhibitors and over 103,000 professional attendees from an estimated 150 countries. At the Arab Health Exhibition in 2017, Ddu boosted 213 business deals through O2O (online to offline) exhibition methods like displaying 3D product models and instant enquiry communication. Over the past year, Ddu has realized the up gradation and breakthrough of Ddu 1.0 to Ddu 3.0, which includes a brand-new visual optimization of the Ddu home page and enhancement of RFQ functions. Besides Ddu’s official website home page, the company page and users’ backend system is currently in the process of being upgraded too. In addition to this, Ddu launched the Ddu Global Promotion Plan, Ddu Credit Verification, Ddu Trade Accelerator and, in 2018, even more third-party service agents will collaborate with Ddu, thereby attracting over 300,000 people engaged in the medical trade from all over the world. And what surprises can we expect from Ddu’s attendance at this year’s Arab Health Exhibition? According to the Ddu management team, Ddu will be attending the expo with a number of our priority members’ products, revealing an intelligent experience of medical trade for all attendees. “Arab Health is the largest international and professional exhibition in the Middle East and we aim to take this opportunity to explore the international medical market for our users”, was the statement made by Ddu management also saying that they have prepared thousands of brochures of their priority members which will be distributed by their staff throughout the entire event. At the Ddu booth, exclusive promotional space will be designated for high priority members to display samples of their products and advertise on the light box (to ensure they receive maximum exposure). Ddu staff will also be recommending users on the Ddu platform according to the demands of clients. If you aim to expand your business into the international medical market, why not try Ddu’s joint-exhibition package? Attend the Arab Health Exhibition 2018 in collaboration with Ddu and enjoy comprehensive online-to-offline promotional services during exhibitions. Here are the service packages: Official Website:www.drugdu.com Hotline:400-106-9990 E-mail:business@drugdu.com About Ddu Ddu (DrugDu- Leading Global Pharmaceutical & Medical Device Platform (DrugDu- Leading Global Pharmaceutical & Medical Device Platform) is a leading global B2B online platform focused on the cross-border trade of pharmaceuticals drugs and medical devices. As a pioneer in the industry, Ddu is committed to accelerating the circulation of the pharmaceutical and medical device trade around the world, making it simpler and more efficient. With advanced technology and expertise in the international medical trade industry, Ddu has provided a full range of solutions for thousands of global suppliers and buyers to build and develop channels of communication and expand international business opportunities. Source:http://medicaldevices.lofter.com/post/1f36b7d7_12122e6e
  2. "Antimicrobial" is a general term which refers to a group of drugs that includes antibiotics, antifungals, antiprotozoals and antivirals, which are destructive or have inhibiting effect to bacteria, fungi and chlamydia and is one of the most widely used drugs in clinical trials. Today, Ddu, the leading global pharmaceutical & medical device products B2B online platform, brings you the breakdowns on China’s Antimicrobial Drug Import and Export Market Report. 1. General situation of global antimicrobial drug market At present, the global antimicrobial drug market is relatively mature, accounting for 15% of universal drug market shares. What’s more, antibiotics account for the largest share of the global antimicrobial market with antiviral drugs ranking second followed by antifungals. To be more specific, amoxicillin sales came out on top followed by augmentin.Amoxicillin, from world-famous pharmaceutical company GlaxoSmithKline (UK), remains to be the best-selling drug in the world. Antiviral drugs are mainly divided into anti-hepatitis virus drugs, anti-venom virus drugs, influenza virus drugs and anti-respiratory virus drugs, with a major market distribution in North America, Europe, Africa and Asia. The world's largest antiviral market is the United States. In the global market of antifungal drugs, triazole drugs sell well. Triazole antifungal drugs used for clinical treatments are mainly voriconazole, fluconazole, itraconazole and posaconazole. Voriconazole and fluconazole, developed by the Pfizer(US), are deemed to be very important anti-fungal drugs. Due to price reductions, new drugs and the enhancement of drug resistance, the growth rate of anti-fungal drugs slowed down with an annual increase of 5%. According to the statistics of WHO, market sales of anti-fungal drugs were 10.86 billion in 2015, of which the most widely used were penicillins and cephalosporins, quinolones and macrolide drugs. 2. General situation of antimicrobial drugs in domesticmarket Despite slower growth in sales rates of the anti-fungal drugs market, anti-fungal drugs are still the most widely used drugs in clinical treatments in developing countries and still maintain a high-speed growth rate. According to the China Reports Hall, China's anti-microbial drug market reached 211.9 billion Yuan with a year-on-year increase of 8.4% in 2015. At this rate, it is estimated to exceed over 300 billion Yuan by the year 2020. With the improvement of living standards, medical security systems, growing treatment rates and full implementation of new health care reform, the antimicrobial market of China's 22 major cities’ sample hospitals exceeded more than 20 billion Yuan, reaching 2.255 billion Yuan in 2015 with an increase of 4.69% over the previous year. 3. China is a big producer of antibiotics with a steady demand for export of penicillin Europe, South Asia and the United States have been China's three major export markets of antibiotics. The country’s other export markets include Africa, South America, Southeast Asia, Canada and Oceania with the main export products being penicillin, tetracycline, oxytetracycline and streptomycin. Penicillin was the world's first antibiotic applied in clinical trials. For a long time, penicillin was the top selling product in the antibiotics market and was widely used as a first-line antimicrobial drug throughout the world. In China, penicillin is a heavyweight product in the pharmaceutical industry with the greatest production among antibiotics. As one of the world's major suppliers of penicillin, China's export sales in 2015 reached 630 million USD. With the rapid development of the penicillin industry, production of China's other three fermented antibiotic products (tetracycline, oxytetracycline and streptomycin) also experienced the same high-speed growth in 2015 with export sales totaling 250 million USD, 330 million USD and 180 million USD respectively. 4. China is a big consumer of antibiotics, expending half of all antibiotics produced worldwide China is not only a big producer of antibiotics but also a big consumer. According to the statistics of World Health Organization, China consumed half of all antibiotics in the world in 2016 (about 162,000 tons, 91.55 billion USD). In addition to those produced for its own use, China also imports antibiotic, mainly from the USA, Japan and Korea. According to HDM, 50.4% of the antibiotics in China were imported from Merck Sharp & Dohme (USA), Sumitomo Chemica (Japan), Yungjin Pharm (Korea) and JW Pharmaceutical (Korea). The imported products were carbapenem antibiotics like meropenem, biapenem and etapenem. The statistics of China’s customs showed that the amounts of imported meropenem, biapenem and etapenem were 11.9 billion USD, 9.8 billion USD, 10.2 billion USD respectively. 5. Leading companies of antimicrobials Livzon Pharmaceutical Group Inc. One of the top twenty listed pharmaceutical companies in China with a world-class modern pharmaceutical manufacturing base up to the standards of the FDA and EU. Main antimicrobial drug: antibiotics Shangdong Qilu King-Phar Pharmaceutical Co., Ltd. Being the biopharmaceutical manufacturing base invested by Qilu Pharmaceutical Co.,Ltd with approvals from the FDA, EDQM, and APVMA, Shangdong Qilu King-Phar Pharmaceutical Co., Ltd mainly produces antimicrobial drugs and exports them to more than 30 countries and regions in North America, South America, Europe, the Middle East and Southeast Asia. Main antimicrobial drugs: neomycin, gentamicin, micronomicin. Qilu Pharmaceutical Co., Ltd. Qilu Pharmaceutical Co.,Ltd is a large-scale comprehensive modern pharmaceutical company in China with world-leading production capacities. Many of its formulations have been granted approval from drug regulator administrations in the United States, the European Union, Australia, the United Kingdom, South Africa and other countries and regions. Main antimicrobial drugs: antibiotics 6. There is a promising future for export of gentamicin Gentamicin is a representative product of aminoglycosides in antibiotics and has been well received by global antimicrobial companies. So far there are only six antimicrobial drugs that have secured FDA approval for clinical use, they are: gentamicin, tobramycin, streptomycin, neomycin, amikacin and paromycin. Gentamicin, amikacin and tobramycin are mostly used to treat systemic infections by American clinicians. In some western countries such as the United States and Austrailia, gentamicin-based aminoglycoside antibiotics are not only used for clinical treatments but also as veterinary pharmaceutical drugs. In Europe and Oceania, where animal husbandry is well developed, they are often used as feed additives which ensures stable sales in the international market. A great demand for feed additive containing gentamicin and a steady need for medical used gentamicin has developed in recent years. For this reason, Ddu, the leading global pharmaceutical & medical device B2B online platform, believes that there is a promising future for the export of gentamicin. Source:http://pharmaceuticalmedicaldevices.blogspot.com/2018/01/chinas-antimicrobial-drug-import-and.html
  3. 3D Printing Goes Legit with FDA Guidance

    3D Printing Goes Legit with FDA GuidanceIn the past two decades, 3D printing progressed from plastic novelties to prototype parts to wide-ranging additive manufacturing applications. Today, for example, GE Aviation is already producing FAA approved parts for aircraft engines. The health and wellness industry already embraces 3D printed tech inside and outside the body. We’ve seen advances in 3D printed cartilage implants, prosthetics, and more. In early December 2017, the U.S. Department of Health and Human Services Food and Drug Administration stepped in with guidance for industry and FDA staff regarding 3D printed medical device products. Technical Considerations for Additive Manufactured Medical Devices presents exactly what its title denotes: considerations, not rules or laws. Similar to the D.O.T.’s guidance for autonomous vehicles issued last fall, the FDA’s “considerations” are not requirements. The point is further hammered home with the header printed on each page, “Contains Nonbinding Recommendations.” The FDA uses this document type, self-described as “leapfrog guidance,” to share its early reactions and thoughts about emerging technologies. The document further qualifies itself as not addressing point-of-care device manufacturing or biological, cellular, or tissue-based products used or incorporated in additive manufacturing. The FDA guidance does give potential 3D medical device productsmanufacturers a path to follow to prepare for FDA approval. The guidance focuses on three aspects of 3D printed medical devices: design and manufacturing process; device testing; and labeling. The specific steps combine conventional manufacturing and testing considerations with additional elements relevant to 3D printing. This document is the FDA’s way of giving a heads up to anyone submitting 3D printed medical devices to the agency for approval. The guidance gives legitimacy to 3D printed medical technology in general and states, in essence, “Based on what we know today, here’s what’s important to us when we consider 3D printed medical device products for approval.” This will give companies one more tool with which to disrupt the status quo in healthcare. Source:http://blog.sina.com.cn/s/blog_139d16d8f0102xjwo.html
  4. With economic development and the ongoing medical reform, people are becoming more and more concerned about their health care and the diagnostic equipment market in China is growing at a compound annual rate of about 10%. Domestic diagnostic equipment has the advantage in the low-end market field and a relative foothold in the middle market, but there is a great gap between China and foreign countries in the high-end market of diagnostic equipment. Today, Ddu, leading global pharmaceutical & medical device B2B online platform, brings you the import and export report of diagnostic equipment in China. Ultrasonic diagnostic equipment holds an absolute advantage with high exports. Compared with CTs and MRIs, the cost of ultrasonic diagnostic equipment is lower, with characteristics of no trauma and real-time access to the images of human tissue which is widely applied in clinical experiments. According to these statistics, the total trade volume of global imports and exports of ultrasonic diagnostic equipment totaled 8.323 billion USD with a year-on-year decrease of 11.05%, of which import volumes totaled 4.186 billion USD with a year-on-year decrease of 12.40% and export volumes totaling at 4.135 billion USновостной порталear-on-year decrease of 9.65%. China's imports topped the list of simple source imports In 2011, the global import and export trade volume of ultrasonic diagnostic equipment skyrocketed to 2.2742 billion USD. China topped the list with an import volume amounting to 4.762 billion USD whereas import and export trade volumes of ultrasonic diagnostic equipment in Germany and Russia are 2.179 billion USD and 1.598 billion USD respectively. In 2011, China imported diagnostic equipment from 88 countries and regions. The top three countries with the highest import volumes were the USA, Germany and Japan, whose combined volume accounted for 67.43% of the all imports. Regarding the import of diagnostic equipment of Chinese provinces, Shanghai topped the list with import volumes exceeding 2.162 billion USD and accounting for 33.15% of the overall market; Import volumes of Beijing and Guangdong were 1.719 billion USD and 00.639 billion USD, accounting for 26.36% and 9.8 % of the market, respectively. Exports to Asia, Africa and Latin America as a springboard to enter the European market Since 2011, global import and export trade volumes of ultrasonic diagnostic equipment exceeded 21.855 billion USD. Between 2011 and 2015, the United States topped the list, totaling 5.112 billion USD followed by China with a total volume exceeding 2.948 billion USD. Chinese ultrasonic diagnostic equipment companies are gaining domestic market share and are gradually expanding into the international market. Asia, Africa and Latin America, being China’s main export markets, have relatively low requirements for market qualifications and registrations. In order to avoid technical and trade barriers in America and European countries, many companies have begun to use underdeveloped regions such as Asia, Africa and Latin America as a springboard to enter the high-end markets of Europe and America. As the biggest market of ultrasonic diagnostic equipment, Europe and America mainly demand product improvement with a steady increase in the market while developing countries are in need of equipment popularization and product improvement with greater potential. Besides Asia, Africa and Latin America, the USA and Japan are also important exporting areas of China. According to statistics from 2010, China’s export volumes to Japan and the USA were 24.17 million USD and 12.23 million USD respectively. According to the statistics of Chinese customs, China’s total trade volume of medical devices totaled 22.38 billion USD with a slight year-on-year increase of 1.2% while its export volumes exceeded 9.03 billion USD. The export of medical device products such as cardiac pacemakers, medical vehicles, kidney dialyzes and so forth, have seen a year-on-year increase of over 36%. Here is the list of main export companies: Prospect: preferred development of ultrasonic devices to enter the high-end market With the increasing investment in the medical industry, China has made obvious progress in the variety of products, technology levels and product quality, expanding its export scale and decreasing the medical equipment trade. Given the great disparity between the Chinese market share of ultrasonic diagnostic equipment and that of foreign products, Ddu suggests that China should vigorously develop imaging performance, image resolution and other basic ultrasound imaging technology, especially new beam synthesis technology, ultrasound imaging technology and flexible imaging technology. In this way, we can further enhance the technical strength of China's ultrasound equipment to meet the needs of developing countries like Asia, Africa and Latin America while gradually expanding the high-end market of the developed countries. This article is from Ddu News, only for non-commercial use and reproduction. Please indicate the source when distributed. Source:
  5. Why do you always lose clients?

    The vexing problem of how to increase the loyalty of clients has always been troublesome to people specializing in foreign trade. Salesmen often find that their clients may say goodbye to them and end their business relationship, simply to start a new one and on other occasions, their clients disappear without any notice. In order to mitigate issues such as these, we should know what causes this behavior and how to remedy the problem. The costs of developing new clients is considerably higher than the costs of maintaining the ones you already have, but many companies strap their cart before the horse way too soon by continually chasing after new client and neglecting the ones they already have. Retaining the trust and loyalty of your old clients will end up being the foundation of your company. Client loss stems from both internal and external factors. Internal factors: Unstable productor serviceYour company’s product or service provides the standard by which clients can measure you and what clients are looking for is high quality. Competition is fierce for companies engaged in the pharmaceutical or medical devices trade and if they fail to raise the bar of their standard, not meeting the expectations of their clients, client loyalty will be a complete impossibility. Lack of service consciousness.Behaviors such as unprofessional attitudes, unanswered questions, ignoring clients and not addressing complaints are all contributing factors to client loss. The interests of buyers and suppliers are closely connected and low service standards can cause great damage to a company’s reputation and may inevitably lead to major client losses. Never take the finer details and basic good manners for granted. Lack of innovation.Because of maturing markets and the increasing transparency of product price, profit margins are becoming smaller and smaller. If companies become too set in their ways, their lack of adaptability may lead to clients looking for more attractive business deals. After all, relationships are maintained by keeping the interests of both parties involved. Unstable employee base.Due to carelessness and lack of standardization of companies when they are dealing with clients, they often don’t exert enough influence and impress their clients. As a result, once a specific employee leaves the company, they often take their clients with them. If you don’t pay attention you will end up being very surprised by the number clients you lose due to employees' who job hop. External factors: Clients are faced with new propositions. There are a limited number of clients in every field and gaining them as your clients becomes the main objective. Every brand or product has a weakness and once yours has been discovered by your competitors, they will take advantage and exploit it. Because of the intense competition and in order to get in on the main market, they will try to attract clients with all the resources available to them, regardless of the cost. Natural wastage. Some client loss is a result ofnatural wastage. For instance, clients may change their jobs or careerThere are numerous resources available to foreign trade companies to determine the possible causes if they experience client losses. Follow ups and conscious investment in client relationships are priceless. Companies who make an effort to address concerns and provide good after-sales services will see positive results. This will all be pointless though if the same mistakes are continuously repeated. Of course, the upkeep of client information is crucial. People move and change contact information and making an effort to keep this updated will help secure them as loyal clients. One on one calls always brings a more personal touch and speaking to your clients directly is a valuable way making them feel appreciated. When experiencing client loss, it advisable for companies to reflect on the internal factors first and try to analyze the situation in order to get to the root of the problem. Reach out to clients who have left and ask for feedback on both products and services to determine what they were not satisfied with. Quality of products. Companies specializing in medical devices products who guarantee the safety, accuracy and durability of their products are able to gain an advantage to some extent while pharmaceutical companies should ensure the safety and effectiveness of their products. Whether it is vaccine, formulation or other medicine, we should not only control production lines and the timing of transportation but also aspects such as temperature to make sure the whole process is efficient and managed well. Only top quality products can lay a solid foundation for sales and promotions and truly attract and retain clients. After-sale service optimization.Companies should provide first-rate serviceswith high standards. After-sale service plays an important role in the medical devices industry. Adhere to the principle of “customer first” and perfect your after-sale service to impress, inspire confidence and establish trust in your company. Strengthening communication with clients. Companies have an obligation to clients to be candid abouttheir development programs and what they aim to achieve. For example, pharmaceutical companies could decide to make various adjustments to the products of regional markets according to current market .s, which would not only meet the needs of clients but also boost their confidence in your company. At the same time, companies are able to strengthen good relationship by gathering information of clients in detail and managing this information with precision. Only when we understand our clients’ requirement can we really reach the goal of providing a service that will motivate them to stay with your company. Adding marketing value.This requires companies to improve their products, services,personnel and image to increase the total value of their Companies should also establish long-term cooperation plans. Consider using dividends in installments or seasonal and annual rewards to attract clients on the premise of making profits by taking the balance of price-cutting as reward. Innovation.To keep up with constantly evolving markets and .s, companies have to make adjustments to products and be creative, constantly analyzing and focusing on improvement. Both pharmaceutical companies and medical device suppliers should keep track of market shifts and changes so as to keep their operation strategies current and up to date. Source:http://medicaldevices.blog.163.com/blog/static/292882889201801292144684/
  6. Two Former Receptos Execs Launch New San Diego Biotech Startup With $100M Gossamer Bio is launching with $100 million in seed financing and two biotech heavy hitters as leadership. The company is being formed by Faheem Hasnain and Sheila Gujrathi, former chief executive officer and chief medical device suppliers, respectively, of Receptos. Receptos was acquired by Celgene in 2015 for $7.2 billion. Receptos focused on immune and metabolic diseases. Its Ozanimod is under development for multiple sclerosis, ulcerative colitis and Crohn’s disease, although the drug’s development for colitis and Crohn’s disease may have stalled. The $100 million seed round was provided by Omega Funds and a Series A Preferred Stock round co-led by ARCH Venture Partners and Omega Funds. It’s not clear what the company’s focus is. It stated, “Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.” The funds raised will be used to form the company and move toward clinical trials with several early and late-stage drug candidates, as well as to “augment the company’s pipeline,” the company states. “We founded Gossamer Bio with a vision to pursue the development of meaningful products that meet patients’ needs,” said Hasnain, who will be the company’s chairman of the board and chief executive officer, in a statement. “After Receptos was acquired by Celgene in July 2015, we have been thoroughly assessing and acquiring therapies that have the potential to create substantial value. Combining this with our proven track record, we believe that we will be in a position to profoundly impact the lives of patients.” The company’s lead program is apparently Phase IIb/III-ready, but aside from saying that it’s an “oral, once daily therapy targeting specific patients across different indications with the potential for a pipeline within a product,” there are no specifics about disease target. It is inferred that the lead product came out of Omega Funds. “We are very excited to partner with Faheem, Sheila, and their team in this new venture,” said Richard Lim, managing director of Omega Funds, in a statement. “Gossamer Bio is precisely the type of company targeting severe unmet needs in which we aim to invest and we look forward to working with this exceptional team to deliver long-term value. We are proud and pleased to have provided Gossamer Bio’s seed capital, as well as the company’s lead clinical stage program.” Lim and Otello Stempacchia, also of Omega Funds, will join Hasnain and Gujrathi on the board of directors. Also joining the board will be Kristina Burow and Robert Nelsen of ARCH Venture Partners, and Tom Daniel, former chairman and president of Celgene Global Research and Early Development. Gujrathi will act as president and chief operating officer. “We are thrilled to launch and build a new company with the core mission of developing innovative therapies and being of service to patients who are suffering,” Gujrathi said in a statement. “We are honored to be working with the world-class team that we are assembling at Gossamer Bio, and we are driven to deliver on our commitments to our patients, our shareholders and each other. Source:http://www.lofter.com/lpost/1f36b7d7_1203f756
  7. Ddu College–Market Report of Coronary Stents

    According to the statistics of the World Health Organization (WHO), about 17.7 million people worldwide died of cardiovascular disease in 2015, accounting for 31% of the global death toll, making it the deadliest disease in the world. Coronary heart disease is a common illness of cardiovascular disease which is treated mainly through medicines, coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). Remarkably, PCI is preferable to both clinicians and patients for its short treatment course, small wound and significant therapeutic effects: doctors can use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque without thoracotomy. Today, Ddu is going to share the market report of coronary stent with you. I. Coronary stent market in China The incidence of coronary heart disease in China has been close to that of the United States and other developed countries. At present, the number of domestic coronary heart disease patients reached 20 million with an increase of more than 1 million new patients each year. In 2016, there were more than 1.2 million PCI cases in China. Cardiac stents are high value consumables used for the treatment of cardiac atherosclerosis. With an increasing incidence rate of coronary heart disease and the improvement of medical technology, more and more people receive PIC treatment. At the same time, an increasing number of people are now able to afford heart stents due to price reduction and improvement of life standards, contributing to the dramatic development of the market. The number of PCI cases which require heart stents increased from 300 thousand stents in 2008 to 1.6 million stents in 2016, of which 93% were drug-eluting systems. In 2016, per capita use of stents in PCI operations remained at 2.2/person and the domestic demand for cardiac drug stent systems will show a rapid growth in the future. II. Global market of coronary heart stents Products of coronary heart stents are popular among patients. In 2016, the global market of coronary heart stents reached 10.6 billion USD. Although many medical device suppliers and companies are constantly developing new coronary stents, this market is dominated by several major medical giants such as Abbott Vascular, Medtronic, Boston Science, Parsons International and Tyler. In terms of clinical use, doctors think highly of the products from Abbott Vascular and Medtronic, both for their characteristics and brands. Lepu Medical from China is also popular but still trails behind Abbott Vascular and Medtronic. III. Steady export of coronary heart stents With successive breakthroughs in the technology of drug-eluting stents, domestic companies like Lepu have rolled out products with IPR and have gradually entered into a stage of mass production and exports. According to custom data, China’s drug-eluting export business has been expanding for the past couple of years with the number of its exporting countries increasing from 22 in 2013 to 65 in 2016. During January 2016 to July 2017, China’s coronary heart stent export sales of the top ten countries it exports to, exceeded 12.78 million USD. IV. China’s benchmarking companies Most Chinese companies are doing well in regards to international market development. Here follows a list of some of the benchmarking companies in this industry (in no particular order): 1. Lepu Medical Technology (Beijing) Co., Ltd. Established in 1999, Lepu Medical Technology (Beijing) Co., Ltd. specializes in high-tech medical device products development, production and sales. Lepu has built up a leading group company concentrating on cardiac therapy, with products including interventional cardiology, occlusion devices, prosthetic heart valves, pacemakers, cardiac in vitro diagnosis products, angiographic equipment and anesthetic products. In Oct. 2009, Lepu successfully listed on ChiNext of the Shenzhen Stock Exchange market (stock code: 300003). 2. LifeTech Scientific Corporation LifeTech Scientific Corporation is the leading supplier of minimally invasive interventional medical devices to treat cardiovascular and peripheral vascular diseases. The company specializes in R&D, manufacturing and sales and its high-quality, innovative, proprietary products are extensively marketed in the world by distributors, spread across Europe, South America, Asia, Africa and other regions. At present, the company is the world’s second largest supplier (and the largest among BRIC countries) of occluders to treat congenital heart diseases. 3. MicroPort Scientific Corporation MicroPort Scientific Corporation can trace its origin back to 1998 to a small office at ZJ Hi-Tech Park, Shanghai, China, where a group of dedicated individuals joined together with a common belief that advancements in medical technology could transform and enhance patients' well-being, not just in China, but globally. During the past decades, the pioneers of MicroPort® have devoted themselves to this mission of advancing the forefront of technology innovation to develop the best and most affordable medical therapies to treat patients around the globe. 4. Sino Medical Sciences Technology Incorporation Sino Medical Sciences Technology Inc. (SINOMED) is a global company engaged in research and development, production and sales of interventional medical devices. SINOMED was founded in 2007 by Dr. Jianhua Sun (CEO) with shareholders who are renown international institutional investors. Heart stents developed by SINOMED with complete IPR, redefined China in the world as an inventor instead of an imitator. V. Development . of stents With more and more drug-eluting stents being applied for clinical use, its excellent clinical efficacy has brought great encouragement and hope to both doctors and patients. Although the first generation of drug-eluting stents (DES) effectively reduced the rate of intravascular restenosis, it still delays the repairing of endothelium when it manages to inhibit the proliferation of vascular smooth muscle cells, thereby increasing the risk of thrombosis caused by the stent. Recent clinical studies have shown that the mortality rate caused by late thrombosis of DES is to some extent higher than that of bare metal stents. So what is the ideal drug-eluting stent and how would it be developed in order to meet the demands of clinicians? Ddu will now discuss how the improvement of DES casts, impacts clinical efficacy from the perspective of design and R&D of manufacturer.. According to our observations, polymer accounts for stent thrombus in the late stages. Attempting to eliminate or reduce the negative effects of polymer has become a main point of focus for doctors and stent manufacturers. Please look at the following examples. Nevo, J&J’s stents (USA) of the latest generation, are composed of slotted stents made of cobalt-chromium alloy and PLGA + Sirolimus coating. Medtronic’s stents (USA) of the latest generation, are designed with no polymer layer. The Resolute Onyx DES is the first and only DES to feature Core Wire Technology, an evolution of Continuous Sinusoid Technology (CST). CST is a unique Medtronic method of stent manufacturing, which involves forming a single strand of cobalt alloy wire into a sinusoidal wave to construct a stent. This enables greater deliverability and conformability to the vessel wall. With Core Wire Technology, a radiopaque inner core is incorporated within the cobalt alloy wire, to enhance visibility for accurate stent placement. Core Wire Technology also enables thinner struts while maintaining structural strength. The Resolute Onyx DES is designed with the transradial approach (through the wrist) in mind, including 5 Fr catheter compatibility with stent sizes up to 5.0 mm. With the first 4.5 mm and 5.0 mm DES sizes available in the U.S., the Resolute Onyx DES helps expand treatment options for patients with extra-large vessels. The fourth-generation SYNERGY™ Coronary Stent from Boston Scientific, uses a bioabsorbable PLGA polymer and everolimus drug formulation to create a thin, uniform coating confined to the outer surface of the stent. Once the drug has been delivered, the bioabsorbable coating is resorbed into the body, leaving behind only a bare-metal stent. This technology is designed to provide the same degree of restenosis reduction as a conventional drug-eluting stent, while offering faster and more complete vessel healing after stent implantation. The SYNERGY Stent features the same proprietary platinum chromium alloy and innovative stent design used in the PROMUS® Element™ Stent to enable thinner struts, increased flexibility and a lower profile while improving radial strength, recoil and visibility. In addition to that, fully absorbable coronary drug-eluting stents are mainly divided into fully absorbable polymer scaffolds and fully absorbable alloy stents. Their representative products are Abbott's polymer biodegradable scaffold BVS and Biotronik. magnesium base alloy drug-eluting stent AMS respectively. The Absorb GT1 Bioresorbable Vascular Scaffold (GT1 BVS) System is a fully absorbable stent mounted on a balloon dilatation catheter. It is made of an absorbable polymer, poly (L-lactide) (PLLA), with a thin coating of the absorbable polymer poly (D, L-lactide) (PDLLA) containing the drug everolimus. The absorbable stent contains two platinum marker beads, one embedded at each end. The delivery system is comparable to the one used in Abbott Vascular's XIENCE Alpine Coronary Stent System (CSS) (P110019/S066). The absorbable stent is placed into a blood vessel (coronary artery) during angioplasty to help keep the coronary artery open. The stent dissolves and will be absorbed by the body in approximately three years, leaving behind only the platinum markers. Biotronik's magnesium-based alloy drug-eluting stent AMS 3.0 "DREAMS" is made of 93% magnesium and 7% rare-earth metals. It induces rapid endothelialization, has low thrombogenicity, and a degradation time of 2-3 months. Magnesium was chosen because it is an essential mineral in the body (the body requires approximately 350 mg/day) and the stent is made of < 4.5 mg of magnesium. The alloy also has calcium antagonist and antiarrhythmic properties and, of importance, is not associated with any adverse allergic reactions. To conclude, the development . of DES is to realize completely elimination of negative effect of polymer or even scaffolds to human beings. source:http://forums.delphiforums.com/medicaldevice/messages/22/1
  8. Five Tips to Create Better Quotes

    Offering a quotation to a client is not always as simple as it sounds and may take some time to master. As with most things in life, the key is to keep practicing and to gain experience because, as you know, practice makes perfect. So how can we swiftly attract clients and ensure effective communication with potential medical device suppliers in a short amount of time? Below are our 5 tips which may come in handy. Know yourself as well as your client Firstly, we should have a clear understanding of what clients are looking for, whether they are interested in goods or whether they have come to see what we offer and compare our prices with other service providers. Don’t be too anxious to justify the price. Clients often have preconceived ideas of a price so rather than going on a tangent to explain all that the offer entails, take another course of action. We all know that we should have a clear understanding of a client’s company. This will allow you to predict whether a client will accept the quotation you offer. If a client is willing to pay $1 for a vaccine and yet your quote was 4 times that, odds are they will reject your offer and so alternative methods of persuasion would be necessary. Be confident in your products Do you really know your products? Do you know the advantages and disadvantages of every product? Being informed about every aspect of your product allows you to speak about it with confide nce. There is nothing feebler than a sales consultant who is uninformed about their own product. Even if your product is of a much higher quality than all its competitors, badly informed sales personnel will sabotage your sales. Make good use of advantages Being knowledgeable about your own product is not where it ends. You will have to know your competitors’ products too. Know the advantages of your product and know how to explain the benefits your product holds over those of your competitors. Although there may be certain aspects in which your product is inferior to others, the advantages should be emphasized when comparisons are made. Keep in mind not to deny the inferior aspects as this will create distrust with the client. Consolidate step by step Once you have reached the point where you are able to give a quotation, be ready for the client’s counteroffer. Be sure to quote a reasonable price as over quoting may cause the client to lose interest and result in you losing the transaction. Also keep in mind that offering a quotation that is too low won’t benefit you or necessarily stop counteroffers from the client. Client’s psychology All clients want to get the best deal they possibly can and will try a wide range of tactics in order to get it. One way of doing this may be to tell you about an absurd offer they got from one of your competitors, one you cannot compete with. Not to worry. Don’t compete and shoot yourself in the foot, rather explain why your product is superior as well as other features such as after-sales services. About Ddu Ddu (www.drugdu.com) is a leading global B2B online platform focused on the cross-border trade of pharmaceutical and medical device products. As a pioneer in the industry, Ddu is committed to accelerating the circulation of pharmaceutical and medical device trade around the world, making it simpler and more efficient. With advanced technology and expertise in the international medical trade industry, Ddu has provided a full range of solutions for thousands of global suppliers and buyers to build and develop channels of communication and expand international business opportunities. source:http://forums.online-sweepstakes.com/blog.php?b=70027
  9. September 18, 2017 Source: Ddu 183 After attending Shanghai CNEF and Hospitalar in Brazil you come home and look at the pile of name cards and the masses of client information you collected. Now what? We often establish new business relationships at exhibitions such as these but the key of securing them lies in how you follow up on your clients. Ddu (www.drugdu.com), the leading global pharmaceutical drugs and medical device products B2B online platform, today shares with you some insight on how to organize client materials and write your first follow up development letter. I. Organize and follow up on your clients with purpose The first step is to collect as much information as possible and pay special attention to all the relevant details at the exhibition. For example, what the client is looking for, what they are most concerned about, what kind of products and suppliers they have in mind and which business partners they would like to keep. After this you will be able to arrange the information according to clients’ interests and the thoroughness of information to help prioritize who to contact first. This will also help you to send them e-mails with content specifically addressing their needs. You can divide your clients as follows: Buyers who ink deals at the exhibition In the event that a client signs a contract at your booth, you are required to keep in touch with them. Regularly contact them to keep them up to date with the latest developments and to remind them of remittance. Potential buyers Many potential buyers will tell you exactly what they are looking for such as details about their desired products and price ranges. It would be wise to give priority to these clients since it’s clear that they are not browsing but ready to buy. Do thorough research on all the client’s key concerns before relying make sure that all samples are well prepared and updated. Learn all you can about the client and be sure to visit their website to get a clear understanding of who they are and what they do. Clients who show only slight interest by exchanging name cards and asking for product information. There are of course a number of people who leave their contact information and only show a bit of interest in your products rather than committing to you. Never underestimate the potential of these individuals and be sure to send them detailed product information and express your goals and willingness to do business with them. II. Do not expect too much from a development letter Generally speaking, clients are very willing to do business at exhibitions since they have the opportunity to speak to you as well as view and experience your products and services first hand. The purpose of a development letter is however more targeted since you now have all the clients’ information and understand what their interests are. When writing a post-exhibition development letter, we suggeststicking to the following three principles: 1. Concision The content of a development letter should be concise and no more than three paragraphs. 2. Simplicity Explain your idea in a clear and simple way to ensure that no words are mistaken especially if they are not English speakers. 3. Precision Don’t beat around the bush and go straight to the point. III. Make your development letter cut to the chase Besides sticking to the three principles above, be sure not to overload the development letter with irrelevant details. 1. Get straight to the point Introduce yourself and your company to the client briefly. 2. Highlight the products of interest Affixed detailed information and quotations of products including parameters, sizes and packing material. 3. Create a detailedcatalogue and catalogue classifications in PDF format and be sure to archive images and bestsellers. 4. Add your name card Affix an imageof your name card as well as the name card of your client to help make a deeper impression. The format of your development letter should firstly lead your clients to check the quotation directly and inform them that samples are available at any time. Secondly, since the quotation is attached, it’s not necessary to mention the MOQ for the time being. Lastly, remember to include alternative contact information like a telephone number, email address and website. This is Ddu’s suggested development letter template: Dear David, Good day! We were pleased to meet you at CMEF Shanghai and enjoyed our conversation. ****. We are ABC Co., Ltd from Shenzhen, China. Our company has been specializing in APIs for 10 years. We are currently a supplier of EFG and would like offer our services to you too. FREE SAMPLES & CATALOGUES will be sent if needed. We look forward to your reply and working with you in future. Best Regards Alice Sales Manager Often you don’t receive a reply to the email in which case it is advisable to phone them. From here on out you will be able to build a professional relationship with your newly acquired clients and so expand your business in the international market. This article is from DduNews, only for non-commercial use and reproduction. Please indicate the source when distributed. Source:http://forums.delphiforums.com/medicaldevice/messages/15/1
  10. How to Develop The Indonesian Market?

    How does the salesmen do the job to help the company promote the existing drug to the local market after the company makes the decision to enter the Indonesian market?It is a common problem that concerned us. As a global pharmaceutical and medical device products B2B pl B2B online platform, Ddu invited Sherlock Chen, a senior biotech practitioner, to talk about how to develop the Indonesian market. Sherlock Chen is engaged in the biological products industry for 20 years. He is familiar with the processes of development, registration, sales of vaccines, blood products,etc. Preparations Work Preparatory work is needed for the development of the Indonesian market, which is consistent with the development of other market. Here are the following points: Overall Research of The Country Situation To research the population and age distributions of Indonesia; To research the major drugs and morbidities of relevant diseases in Indonesia; To research the coverage of Medicare in Indonesia. The steps mentioned above can help to understand the disease situation as well as the drugs’ potential market demands in Indonesia. Registration of The Drug It is better to study registration regulations to well know about the conditions and product documentation required for Indonesian drug registration. Halal Certification With a large population of Muslim in Indonesia, halal certification is needed for drugs and food. Indonesian Muslim Congress, the Indonesian Muslim supreme organization, established the LP.POM-MUI (Food, Drug, and Cosmetic Assessment Association). LP.POM-MUI, as an independent organization, researches, investigates and tests all the information on the application of the halal certification , and then submit the results to the MUI. Finally MUI issues the Halal certification. Halal certification steps are as follows: The enterprises should firstly know about the basic knowledge of halal certification; Download and fill the application form; Submit the form to be reviewed by MUI Indonesia headquarters; Sign the agreement and make the payment; Experts of MUI experts audit the factory on site and collect samples for analysis on experiment; Samples will be sent to the IPB (Bogor Agricultural University) laboratory by auditors and be analyzed on the relevant component ; Auditors will submit the audit report to the MUI Fatawa Committee. MUI headquarters issue a halal certificate; After getting Halal Certification, it is time to do the registration. The Indonesian registration includes pre-registration and registration. In the pre-registration phase, the Ministry of Health BPOM determines the type of the drug belongs to and conducts a formal review based on the active ingredient. New Drug : it needs 100 working days for the registration of Life Saving Drug. It cost 150 working days if the drug has been registered in the EU or has been sold in two countries with good assessment system ( assessment report is needed, which issued by the US FDA, the European Union's EMEA, etc.). It needs 300 working days for the other cases. Copy Drug : 80-150 working days is required for drugs that has similar products under sale or production. It needs 80 working days for those that are only exports to other countries. 100 working days is needed for those that are in the national list. It costs 150 working days for the other cases. Biological Product For registration, Indonesia is one of the ASEAN countries, whose documents should in accordance with ACTD format. Similar to CTD, there are just some differences in terms of the format. CTD format: Part I: Administrative and Prescribing Information Part II: Overview and Summary of Modules 3 to 5 Part III: Quality (Pharmaceutical Documentation) Part IV: Preclinical (Pharmacology/Toxicology) Part V: Clinical - Efficacy (Clinical Trials) Part I, II, III and IV of the CTD format are equivalent to Part I, II, III and IV of the CTD format. They are about the management, the quality, the preclinical and clinical parts. After the preparation of the registration documents, BOPM will review the information. They may ask you to hand in supplemental information. Then it comes to the inspection. BOPM will send experts to do on-site inspection. They will make the report on-site. The factory complete the rectification report and submit it on time. If it is passed, the registration is successfully finished. Production of Promotion Material After determining the appropriate drug for Indonesian market, the next step is to start making promotion documents. Add some product information like the market sale, product features and other information to the promotion documents, so that potential agents could better know about the product. As a hint, there may be much information in some promotion documents, such as company qualifications, certificates, influence, etc. But these qualifications are mainly issued by the Chinese local institutions, with little international influence which attracts Indonesian agents rarely. They usually focus on basic information such as dosage form, indications, storage temperature, validity period, integrity of registration file, sales status in China, countries of export, registration status in developed countries, international certification, and the advantages compared with similar first-line products. All these information will help customers to assess the market potential of the product, the registration difficulty, the promotion difficulty and the profit opportunity. Excavation of Potential Agents Search for agents is the next step after the preparatory work. There are a variety of ways to find potential agents as well as their contact information, such as: Professional exhibitions, such as CPhI, KIMES, etc. Search engines, such as Google、Yahoo, etc. Social platforms, such as Facebook、LinkedIn, etc. B2B platforms, such as Alibaba (comprehensive B2B platform), Drugdu (pharmaceutical drugs and medical device products B2B platform), etc. This process requires patience. When you can not directly find the target, you can try to use the search engine or social platform to find the agent company, then contact. The communication may be started by email, telephone, social platform, etc. Cooperation Negotiations During the communication with potential agents, we could recommend the products and ask about which product information they focus on. At the same time, it is necessary for salesmen to have comprehensive knowledge about the product, so that important details could be quickly told to the agents. They will show more confidence for the market and the product as long as they have comprehensive knowledge about the product. Reach of Agency Agreement After winning the agent’s confidence of the product, the next step is the negotiation process of the agency agreement. It may cost long time before signing the agreement, which is filled with not only expectation but also bargaining. As the global leading pharmaceutical and medical device B2B online platform, Drugdu.com wish you successfully step into the Indonesian market. Source:http://media.drugdu.com/market/how-to-develop-the-indonesian-market.html
  11. How to Establish A Good Relationship with Your Suppliers

    There are three major and indispensable elements in foreign trade: supply, market and clients. As an international trade company, it’s necessary to establish good relationship with medical device suppliers since our goal is to collaborate with them for support in marketing and product supply. As more and more people attach greater importance to negotiating with clients, the role of suppliers should not be overlooked. In actual fact, establishing ties with suppliers is an act of creating professional friendships and various factors come into play. 1.Professional attitude Dealing with suppliers requires respect and professionalism as these are the building blocks for any good relationships In our industry, there are times when certain products are in high demand. Situations such as these often lead to tense situations where clients expect you to deliver. This challenge allows you to prove your efficiency and ability to deal with pressure. In one such situation, our clients were desperate, resulting in a lot of pressure on the suppliers but, staying calm and doing everything necessary, our staff were able to meet the clients’ demands while maintaining a professional business manner with our suppliers. In fact, the supplier was so impressed that he stated how much he valued the attitude of our staff and asked whether they would be willing to give some tips to his lazy son in order for him to retire! Starting out, your best tool while building a reputation, is your professional attitude. Stay humble, be eager to learn and communicate with clarity and purpose. 2.Share the company vision Communicate your future vision with your suppliers as well as how you work towards improving your services. Inform them of ventures such as online publicity, amount of investment, consumer coverage. If you have services such as selective participation at exhibitions and frequent visits to international clients that they could benefit from, tell them about these to ensure they have full access to everything you offer. Informing them of various marketing campaigns and past successes, helps to assure them of your efficiency and commitment to promoting their products in a powerful and impactful way. When they know what your vision is, they can join your journey with confidence. 3.Maintain contact and communication Clear and purposeful business communication inspires trust and opens up opportunities for feedback. Keeping suppliers up to date on the latest progress and their orders confirms that your are competent and they can trust you with their business. 4.Involve the factory We often take our clients to the factory to give them a clear understanding of where their products come from. This started out as a simple gesture and has become such an intricate part of our client relationships that we now have staff dealing only with factory visits. This practice gives your client a clear indication of what happens ‘behind the scenes’ and proves your insight and ability to deal with the various aspects of the business. 5.Be smart about your business deals. We should be modest and work together with the factory for the common goal of providing customers with the best quality service and should not treat the supplier as merely an order taker. Thus, besides strategic negotiations, emotional intelligence is crucial. Anyone who wants to succeed in business needs to understand the important role emotional intelligence plays in business relationships. That being said, your own interests are important too. There is no point in shooting yourself in the foot because you want to make a good impression. Be sure that you still make your own profits when striking a deal. 6.Solve problems instead of shifting blame. Problems occur in any business. Our first response is to give the blame to someone else but a much more constructive way of dealing with an issue is to look for a solution. If a simple solution can mitigate the problem, then harmony can be maintained. 7.Help each other out Many hands make light work. Assist each other and offer help when something goes wrong. Your ability to deal with unforeseen issues can ensure a long and healthy working relationship with your medical device suppliers. If you establish the competence of your company from the get go, orders will follow! Source:http://forums.delphiforums.com/medicaldevice/messages/13/1
  12. In which industry is the next unicorn company most likely to be born into? With the arrival of an aging society, medical trade is regarded as the industry with the most potential to produce a unicorn company.In the cross-border medical trade industry, Ddu, the first global cross-border pharmaceutical and medical device B2B platform, recently announced the completion of their pre-A round of financing. Terry Yuan, the CEO of Ddu publicly said: "In the search of the vertical market, Ddu is more professional and knowledgeable than Baidu in medical trade and is excepted to subvert traditional industries like Didi and so we took the name of the two-words, naming our platform "Ddu ". Solving the traditional cross-border medical trade problems Didi has utilized the Internet to successfully optimize the traditional car rental industry within four years which was approved by society, government and insiders. In a similar way, the traditional cross-border medical trade industry is in urgent need of transformation in the face of many difficulties such as asymmetric information, liquidity problems, limited resources and so forth. As the first global cross-border pharmaceutical and medical device B2B platform, Ddu leverages its brilliant and unmatchable resources to develop global markets and promote brand globalization through product displays, supply and demand displays and professional services. From its founding moments, Ddu has been committed to providing personalized cross-border medical trade services to assist global buyers in find products and suppliers quickly and efficiently. After only one year of rapid development, Ddu has helped over 10,000 registered members with more than 1,000,000 deals. Insiders have said that there is a huge market for cross-border medical trade. A conservative estimation of pharmaceutical transactions in the USA is about 5 trillion per year/ month / day which is the highest number of transactions in cross-border e-commerce. These transactions are 4 times higher in the global market. The emergence of Ddu solves the problem of asymmetric information from the two transaction sides as well as low efficiency amongst other things, thus promoting the overall development of the medical trade industry. Ddu has become the industry model in cross-border medical trade e-commerce industries from regarding both number of users and appraisals. All these factors combined, point to the rising of a new unicorn. A more professional medical trade platform than Baidu Although the "B2B 2.0 era" has been the focus of much hype, the match making trade seems to be lagging behind the times, which is precisely the issue within medical trade industry. For information asymmetry, Ddu provides users with a search engine service similar to Baidu. Once users enter the product name, Ddu will provide the information of corresponding buyers, suppliers and agents automatically. According to reports, Ddu offers the most accurate, comprehensive and updated databases of global medical devices & pharmaceutical information, with easy access to over 1,000,000 hot medical products and the information of 100,000 medical devices & pharmaceutical companies from over a 100 countries and regions. Our Mission “Ddu is a much more professional and suitable search tool for the medical trade industry than Baidu”. Unlike Baidu's comprehensive search, Ddu enables users to target their searches with more precision. Taking the word "injection" as an example, (injection having a lot of meanings in English) search engines usually retrieve a lot of useless information. Users have to replace or add keywords in order to find the results they want. The emergence of Ddu has now overcome this weakness. In order to facilitate users to browse and query, additional category searches are available in Ddu. Based on experts' opinions, products have been divided into 2 main categories namely medical device and pharmaceutical along with 100 subcategories helping users to find exactly what they are looking for. Moreover, 14 national labels are helpful to users in choosing products from the searching results. This intelligent service fully reflects the importance placed on searching experience by Ddu. The upcoming credit guarantee system is anther innovative feature which provides users a with a more efficient and accurate searching service. “We are currently discussing the credit guarantee system with well-known certification companies, SGS and TUV, credit company Dun & Bradstreet as well as insurance company, Sinosure and substantial progress is anticipated for June”, reported Mr. Yuan. Ddu hopes to better leverage the B2B online platform to help users control the risk of medical cross-border trade transactions. Online & Offline Promotion Ddu lays much emphasis on the optimization of its fast match service. Just post the buying offers and the automated system will swiftly match the suppliers or agents. The option reduces the time to reach partners, meet the individual needs of buyers and analyze the information between buyers and suppliers. Ddu exhibits at least once a month at most of the fairs related to global pharmaceutical and medical device, enabling pharmaceutical and medical device companies to expand their business overseas and promote their brands globally. Users can release the buy offers and agent targets through scanning codes. Buy offers and agent targets will be collected and updated on a large screen, available for viewing by visitors. Ddu breaks the limitation of time and space and maximizes the efficiency of match making transactions. With excellent and bountiful experiences in medical trade, Ddu is aimed to facilitate the global trade between worldwide buyers and suppliers. Could Ddu do what Didi did four years ago and become the next unicorn? Let us wait and see. Source:http://media.drugdu.com/ddu-news/could-drugdu-com-ddu-be-the-next-unicorn-after-didi-and-baidu-in-2017
  13. 3D printed medical device products are very high-end devices that are engaged in the process of utilizing digital models to develop a three-dimensional object.In the healthcare industry, many academic institutes make use of this technology for patient-specific treatment.The key 3D printed medical devices companies are working on strategies that would increase their market share. In terms of income, the global 3D print medical device and equipment market is expected to grow at a compound annual growth rate of 17.7% during the forecast period, which is expected to reach $1.4694 billion by the end of 2026. (Source: Future Market Insights, 2016)The key companies of 3D printed medical devices in the global 3D Systems, Inc., Arcam AB, Stratasys Ltd., FabRx Ltd., EOS GmbH Electro Optical Systems, EnvisionTEC, Cyfuse Biomedical K.K., and Bio3D Technologies taking innovative creating a successful strategic plan to increase their consumer base. Reasons 3D printing medical devices will have a foothold in the healthcare industry Applications of 3D Printing Medical Device Products 3D printing technology was used for the rapid manufacture of medical models in the begging.With remarkably the development of 3D printing technology, it is used to develop medical devices such as dental implants, orthopedic implants, complex surgical instruments, customized artificial joints, customized surgical consumables and hearing aids. Furthermore, hospitals and academic institutes need various 3D Printed models for training purposes. Unique Features of 3D Printed Medical Devices 3D printing technology not just creates copies of the same device, but makes it easy for designers to make more patient-matched devices without additional tools.The flexibility of 3D printing enables 3D printing medical devices matched to a specific patient with very complex internal structures. There is no unified standard for 3D printed medical devices.FDA still regulates 3D printed medical devices in the same way as traditional medical device products. According to its various applications in the medical industry and its unique features, 3D printed medical devices will certainly have great prospects fit in the future. Source:http://media.drugdu.com/latest-information/market-views/3-amazing-advances-in-pharmaceutical-drugs-in-2017.html
  14. Ddu’s Golden Age in Cross-border Medical Trade

    Under the background of the Internet plus era, Ddu is set up by a a talented team, consisting of experienced insiders and Internet elites. Ddu (Drugdu.com) is a global leading pharmaceuticals and medical devices B2B online platform. Different from comprehensive B2B platforms, Ddu is a vertical one focusing on the medical trade industry. It is a bold attempt for traditional industry to accelerate the transformation and upgrading. With the negative impact of the sluggish demand of external economies, the increasing price competition, the difficulty of industry transformation and so on, pharmaceutical foreign trade grows slowly and faces many difficulties. However, with the gradual implementation of cooperation strategies like the Belt and Road Initiative, a new dawn has been brought to the upgrading of Chinese traditional health care industry. Lots of cooperation opportunities have generated from countries engaging in the Belt and Road Initiative. Health care industry plays an important role in realizing the Belt and Road Initiative, which allows Ddu to act as a crucial part in the cross-border trade of pharmaceuticals and medical devices. Meanwhile, basing on users’ demand, Ddu keeps coming up with new ideas. Ddu launched Online-offline service at the end of 2016, a new model for exhibitions. Global suppliers and buyers got in touch with each other easily and efficiently via 3D stereo model, visual display, instant video communication,etc. Within half a year, Ddu has been well know by the industry. There have been over 8,000 registered members while one quarter of them have enjoyed Ddu’s promotion service, including the well-known monitor supplier Shenzhen Hexin zondan Medical Equipment Co. Ltd. (hereinafter referred to as "Zondan"). Zondan tentatively reached a cooperation intention with Stormoff, Russia's largest medical equipment agent. Terry Yuan, the founder of Ddu, said that whether from the market or from the policy , the pharmaceutical cross-border B2B had stood in the air. It was reported that relative data of Ddu went well in 2016. The number of registration increase with the growth of 25% in the 4th. It will continue to rise in 2017. In the future, what Ddu provides is not only information and database, but also the establishment of a medical and trade ecosystem covering all medical and trade users. In order to solve more traditional medical trade difficulties, in 2017, Ddu will optimize the service on the basis of the following five points: Firstly, establish a database of Chinese suppliers, with detailed categories; Secondly, make a trade credit and supervision system for users; Thirdly, realize fast matching of buy offers and agent intents; Fourthly, build an online center for sharing and training; Fifthly, provide the third-party service, including project investigation, business communication, clinical registration, financial guarantee and logistics warehousing. Source:http://media.drugdu.com/ddu-news/ddus-golden-age-in-cross-border-medical-trade.html
  15. 3 Amazing Advances in Pharmaceutical Drugs in 2017

    As 2017 draws to a close, we look back at a year where advances in pharmaceutical drug therapies brought new hope to people from across the globe. These steps forward bring with them a sense of suspense as we wait for more ground-breaking work to be accomplished in 2018. Here is Drugdu.com’s list of medical advances that amazed. 1. Radicava for ALS As the first new treatment to be approved by the FDA in 22 years, Radicava is first on our list of drugs. ALS (amyotrophic lateral sclerosis) also known as Lou Gehrig’s disease, is a neurodegenerative disease that reduces the functionality of muscles in the body. There are still no cures for ALS but during Radicava’s phase 3 trial, 33% of the patients who received the drug reported a slowing down of functional deterioration, meaning a longer term of independence for ALS sufferers. 2. Experimental drug for Huntington’s disease This fatal genetic disorder causes a degradation of nerve cells in the brain, affecting both physical and mental abilities. The new breakthrough is a drug called ASO-HTT-Rx and unlike other pharmaceutical drugs used to manage the symptoms, it must be injected directly into the spinal cord. It may not yet be commercially available but we are waiting with bated breath for more news on this. 3. Ocrevus and clemastine fumarate for MS MS (multiple sclerosis) is an autoimmune disease of the central nervous system where a person’s immune system attacks myelin (the protective substance covering nerve cells). Ocrevus is used to treat primary progressive MS as well as relapsing MS. Patients taking Ocrevus found that is decreased the progression of the disease more so when compared to Rebif, an anti-inflammatory drug used to treat MS. Although this is great news, there is currently no medication for the repair of myelin but, new research has shown that clemastine fumarate, an antihistamine, may be able to reverse and repair the damage caused even if the disease is well advanced. Source:http://medicaldeviceandequipment.33236.n8.nabble.com/3-Amazing-Advances-in-Pharmaceutical-Drugs-in-2017-td9.html